Literature DB >> 30635297

Telomere length and genetic variant associations with interstitial lung disease progression and survival.

Chad A Newton1, Justin M Oldham2, Brett Ley3, Vikram Anand1, Ayodeji Adegunsoye4, Gabrielle Liu3, Kiran Batra5, Jose Torrealba6, Julia Kozlitina7, Craig Glazer1, Mary E Strek4, Paul J Wolters3, Imre Noth8, Christine Kim Garcia1,7.   

Abstract

Leukocyte telomere length (LTL), MUC5B rs35705950 and TOLLIP rs5743890 have been associated with idiopathic pulmonary fibrosis (IPF).In this observational cohort study, we assessed the associations between these genomic markers and outcomes of survival and rate of disease progression in patients with interstitial pneumonia with autoimmune features (IPAF, n=250) and connective tissue disease-associated interstitial lung disease (CTD-ILD, n=248). IPF (n=499) was used as a comparator.The LTL of IPAF and CTD-ILD patients (mean age-adjusted log-transformed T/S of -0.05±0.29 and -0.04±0.25, respectively) is longer than that of IPF patients (-0.17±0.32). For IPAF patients, LTL <10th percentile is associated with faster lung function decline compared to LTL ≥10th percentile (-6.43% per year versus -0.86% per year; p<0.0001) and worse transplant-free survival (hazard ratio 2.97, 95% CI 1.70-5.20; p=0.00014). The MUC5B rs35705950 minor allele frequency (MAF) is greater for IPAF patients (23.2, 95% CI 18.8-28.2; p<0.0001) than controls and is associated with worse transplant-free IPAF survival (hazard ratio 1.92, 95% CI 1.18-3.13; p=0.0091). Rheumatoid arthritis (RA)-associated ILD (RA-ILD) has a shorter LTL than non-RA CTD-ILD (-0.14±0.27 versus -0.01±0.23; p=0.00055) and higher MUC5B MAF (34.6, 95% CI 24.4-46.3 versus 14.1, 95% CI 9.8-20.0; p=0.00025). Neither LTL nor MUC5B are associated with transplant-free CTD-ILD survival.LTL and MUC5B MAF have different associations with lung function progression and survival for IPAF and CTD-ILD.
Copyright ©ERS 2019.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30635297      PMCID: PMC6612265          DOI: 10.1183/13993003.01641-2018

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  40 in total

1.  The pulmonary fibrosis-associated MUC5B promoter polymorphism does not influence the development of interstitial pneumonia in systemic sclerosis.

Authors:  Anna L Peljto; Mark P Steele; Tasha E Fingerlin; Monique E Hinchcliff; Elissa Murphy; Sofia Podlusky; Mary Carns; Marvin Schwarz; John Varga; David A Schwartz
Journal:  Chest       Date:  2012-12       Impact factor: 9.410

2.  An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management.

Authors:  Ganesh Raghu; Harold R Collard; Jim J Egan; Fernando J Martinez; Juergen Behr; Kevin K Brown; Thomas V Colby; Jean-François Cordier; Kevin R Flaherty; Joseph A Lasky; David A Lynch; Jay H Ryu; Jeffrey J Swigris; Athol U Wells; Julio Ancochea; Demosthenes Bouros; Carlos Carvalho; Ulrich Costabel; Masahito Ebina; David M Hansell; Takeshi Johkoh; Dong Soon Kim; Talmadge E King; Yasuhiro Kondoh; Jeffrey Myers; Nestor L Müller; Andrew G Nicholson; Luca Richeldi; Moisés Selman; Rosalind F Dudden; Barbara S Griss; Shandra L Protzko; Holger J Schünemann
Journal:  Am J Respir Crit Care Med       Date:  2011-03-15       Impact factor: 21.405

3.  Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis.

Authors:  Ganesh Raghu; Kevin J Anstrom; Talmadge E King; Joseph A Lasky; Fernando J Martinez
Journal:  N Engl J Med       Date:  2012-05-20       Impact factor: 91.245

4.  A common MUC5B promoter polymorphism and pulmonary fibrosis.

Authors:  Max A Seibold; Anastasia L Wise; Marcy C Speer; Mark P Steele; Kevin K Brown; James E Loyd; Tasha E Fingerlin; Weiming Zhang; Gunnar Gudmundsson; Steve D Groshong; Christopher M Evans; Stavros Garantziotis; Kenneth B Adler; Burton F Dickey; Roland M du Bois; Ivana V Yang; Aretha Herron; Dolly Kervitsky; Janet L Talbert; Cheryl Markin; Joungjoa Park; Anne L Crews; Susan H Slifer; Scott Auerbach; Michelle G Roy; Jia Lin; Corinne E Hennessy; Marvin I Schwarz; David A Schwartz
Journal:  N Engl J Med       Date:  2011-04-21       Impact factor: 91.245

5.  Mucin 5B promoter polymorphism is associated with idiopathic pulmonary fibrosis but not with development of lung fibrosis in systemic sclerosis or sarcoidosis.

Authors:  Carmel J Stock; Hiroe Sato; Carmen Fonseca; Winston A S Banya; Philip L Molyneaux; Huzaifa Adamali; Anne-Marie Russell; Christopher P Denton; David J Abraham; David M Hansell; Andrew G Nicholson; Toby M Maher; Athol U Wells; Gisela E Lindahl; Elisabetta A Renzoni
Journal:  Thorax       Date:  2013-01-15       Impact factor: 9.139

6.  Telomere lengths, pulmonary fibrosis and telomerase (TERT) mutations.

Authors:  Alberto Diaz de Leon; Jennifer T Cronkhite; Anna-Luise A Katzenstein; J David Godwin; Ganesh Raghu; Craig S Glazer; Randall L Rosenblatt; Carlos E Girod; Edward R Garrity; Chao Xing; Christine Kim Garcia
Journal:  PLoS One       Date:  2010-05-19       Impact factor: 3.240

7.  Telomerase mutations in families with idiopathic pulmonary fibrosis.

Authors:  Mary Y Armanios; Julian J-L Chen; Joy D Cogan; Jonathan K Alder; Roxann G Ingersoll; Cheryl Markin; William E Lawson; Mingyi Xie; Irma Vulto; John A Phillips; Peter M Lansdorp; Carol W Greider; James E Loyd
Journal:  N Engl J Med       Date:  2007-03-29       Impact factor: 91.245

Review 8.  Rheumatoid arthritis-associated interstitial lung disease: the relevance of histopathologic and radiographic pattern.

Authors:  Eunice J Kim; Harold R Collard; Talmadge E King
Journal:  Chest       Date:  2009-11       Impact factor: 9.410

9.  Adult-onset pulmonary fibrosis caused by mutations in telomerase.

Authors:  Kalliopi D Tsakiri; Jennifer T Cronkhite; Phillip J Kuan; Chao Xing; Ganesh Raghu; Jonathan C Weissler; Randall L Rosenblatt; Jerry W Shay; Christine Kim Garcia
Journal:  Proc Natl Acad Sci U S A       Date:  2007-04-25       Impact factor: 11.205

10.  Telomere shortening in familial and sporadic pulmonary fibrosis.

Authors:  Jennifer T Cronkhite; Chao Xing; Ganesh Raghu; Kelly M Chin; Fernando Torres; Randall L Rosenblatt; Christine Kim Garcia
Journal:  Am J Respir Crit Care Med       Date:  2008-07-17       Impact factor: 21.405

View more
  35 in total

1.  Rare Protein-Altering Telomere-related Gene Variants in Patients with Chronic Hypersensitivity Pneumonitis.

Authors:  Brett Ley; Dara G Torgerson; Justin M Oldham; Ayodeji Adegunsoye; Shuo Liu; Jie Li; Brett M Elicker; Travis S Henry; Jeffrey A Golden; Kirk D Jones; Amy Dressen; Brian L Yaspan; Joseph R Arron; Imre Noth; Thomas J Hoffmann; Paul J Wolters
Journal:  Am J Respir Crit Care Med       Date:  2019-11-01       Impact factor: 21.405

2.  Familial pulmonary fibrosis: a world without frontiers.

Authors:  Raphael Borie; Bruno Crestani
Journal:  J Bras Pneumol       Date:  2019-10-07       Impact factor: 2.624

3.  Family History of Pulmonary Fibrosis Predicts Worse Survival in Patients With Interstitial Lung Disease.

Authors:  Claire C Cutting; Willis S Bowman; Nam Dao; Janelle Vu Pugashetti; Christine Kim Garcia; Justin M Oldham; Chad A Newton
Journal:  Chest       Date:  2021-01-21       Impact factor: 9.410

4.  Leukocyte telomere length and mycophenolate therapy in chronic hypersensitivity pneumonitis.

Authors:  Ayodeji Adegunsoye; Julie Morisset; Chad A Newton; Justin M Oldham; Eric Vittinghoff; Angela L Linderholm; Mary E Strek; Imre Noth; Christine Kim Garcia; Paul J Wolters; Brett Ley
Journal:  Eur Respir J       Date:  2021-03-04       Impact factor: 16.671

5.  A nonsynonymous polymorphism (rs117179004, T392M) of hyaluronidase 1 (HYAL1) is associated with increased risk of idiopathic pulmonary fibrosis in Southern Han Chinese.

Authors:  Juan Liu; Yanhan Deng; Zheng Wang; Biwen Mo; Jianghong Wei; Zhenshun Cheng; Qingzhen Peng; Guang Wei; Jingping Li; Ying Shu; Hua Yang; Shirong Fang; Guangwei Luo; Shuo Yang; Yingnan Wang; Jing Zhu; Jingping Yang; Ming Wu; Xuyan Xu; Renying Ge; Xiaoju Zhang; Weining Xiong; Xiaomei Wang; Zongzhe Li
Journal:  J Clin Lab Anal       Date:  2021-05-04       Impact factor: 2.352

6.  Myositis-specific Antibodies Identify A Distinct Interstitial Pneumonia with Autoimmune Features Phenotype.

Authors:  Julia Graham; Iazsmin Bauer Ventura; Chad A Newton; Cathryn Lee; Noelle Boctor; Janelle Vu Pugashetti; Claire Cutting; Elena Joerns; Habrinder Sandhu; Jonathan H Chung; Christine Kim Garcia; Michael Kadoch; Imre Noth; Ayodeji Adegunsoye; Mary E Strek; Justin M Oldham
Journal:  Eur Respir J       Date:  2020-07-16       Impact factor: 16.671

Review 7.  Familial Pulmonary Fibrosis: Genetic Features and Clinical Implications.

Authors:  David Zhang; Chad A Newton
Journal:  Chest       Date:  2021-06-26       Impact factor: 9.410

Review 8.  Recent advances in the diagnosis and management of interstitial pneumonia with autoimmune features: the perspective of rheumatologists.

Authors:  Hong Ki Min; Se-Hee Kim; Sang-Heon Lee; Hae-Rim Kim
Journal:  Korean J Intern Med       Date:  2021-02-08       Impact factor: 2.884

Review 9.  Biomarkers in Progressive Fibrosing Interstitial Lung Disease: Optimizing Diagnosis, Prognosis, and Treatment Response.

Authors:  Willis S Bowman; Gabrielle A Echt; Justin M Oldham
Journal:  Front Med (Lausanne)       Date:  2021-05-10

Review 10.  Interstitial Lung Disease in Connective Tissue Disease: A Common Lesion With Heterogeneous Mechanisms and Treatment Considerations.

Authors:  Tihong Shao; Xiaodong Shi; Shanpeng Yang; Wei Zhang; Xiaohu Li; Jingwei Shu; Shehabaldin Alqalyoobi; Amir A Zeki; Patrick S Leung; Zongwen Shuai
Journal:  Front Immunol       Date:  2021-06-07       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.